We congratulate Cornelius Pompe as our new COO and welcome him as new Board member
Leukocare, a leading provider of drug product and formulation development services, is pleased to announce the appointment of Dr. Cornelius Pompe as its new Chief Operating Officer (COO). In his new position Cornelius Pompe will play a pivotal role in the company’s continued growth as it expands its cutting-edge services to the pharmaceutical and biotechnology industries.
With a deep focus on harnessing the power of data science, bioinformatics, and advanced analytics, Leukocare helps drug developers optimize their drug product formulations and respective processes, improve efficiency, and reduce time-to-market. As COO, Cornelius Pompe will be responsible for the day-to-day operational management of the company. Moreover, he will lead efforts to scale the company’s service offerings, enhance operational excellence, and deliver advanced solutions by extending Leukocare’s data science toolbox to meet the evolving needs of the industry.
Cornelius Pompe joined Leukocare’s management team in 2021, first as Vice President Research & Development and subsequently as Chief Development Officer (CDO). Before joining, Cornelius Pompe held leadership roles at different biotech companies and pharma service companies, amongst others Amgen, Micromet, LFB and Coriolis. He brings over 20 years of experience in the biotechnology and life sciences sectors, with a focus on operational strategy, process innovation, and team development.
"I am thrilled to have Cornelius in my leadership team," said Michael Scholl, CEO of Leukocare. "With his proven track record in pharma services both on client and on provider side, Cornelius is perfectly positioned to further help us build on our strengths and accelerate the impact we have on our clients’ success. His leadership will be essential as we continue to integrate advanced data science and bioinformatics into the drug product development process, enabling our clients to develop more effective and personalized therapies."
"I am excited to further support Leukocare at such a pivotal time in its growth in a new role with more responsibilities," said Cornelius Pompe. “The opportunity to contribute to a company that is at the intersection of cutting-edge data science and drug product development is incredibly inspiring. I look forward to working with the team to enhance our service offerings, build operational efficiency, and continue delivering exceptional value to our clients.”